Repare Therapeutics (RPTX) said late Thursday it is refocusing its resources on advancing phase 1 clinical programs for RP-1664 in solid tumors and RP-3467 in certain types of cancer.
The company also intends to seek partnerships for lunresertib and camonsertib before starting the next trials.
The strategic realignment, combined with cost and headcount reductions, is expected to extend the company's funds of $153 million until mid-2027, it added.
Repare said it will discontinue other lunresertib and camonsertib studies unless a suitable development partner is found.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。